KEGG   PATHWAY: hsa01524Help
Entry
hsa01524                    Pathway                                

Name
Platinum drug resistance - Homo sapiens (human)
Description
Platinum-based drugs cisplatin, carboplatin and oxaliplatin are widely used in the therapy of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. The mechanism of action of Platinum-based drugs involves covalent binding to purine DNA bases, which primarily leads to cellular apoptosis. Their clinical success is, however, limited due to severe side effects and intrinsic or acquired resistance to the treatment. Platinum resistance could arise from decreased drug influx, increased drug efflux, intracellular detoxification by glutathione, etc., decreased binding (e.g., due to high intracellular pH), increased DNA repair, decreased mismatch repair, defective apoptosis, and altered oncogene expression.
Class
Human Diseases; Drug resistance: antineoplastic
BRITE hierarchy
Pathway map
hsa01524  Platinum drug resistance
hsa01524

Ortholog table
Organism
Homo sapiens (human) [GN:hsa]
Reference
  Authors
Siddik ZH
  Title
Cisplatin: mode of cytotoxic action and molecular basis of resistance.
  Journal
Oncogene 22:7265-79 (2003)
DOI:10.1038/sj.onc.1206933
Reference
  Authors
Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Buges C, Bystrup S, Esteller M, Abad A
  Title
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance.
  Journal
Mol Cancer Ther 14:1767-76 (2015)
DOI:10.1158/1535-7163.MCT-14-0636
Reference
  Authors
Kelland L
  Title
The resurgence of platinum-based cancer chemotherapy.
  Journal
Nat Rev Cancer 7:573-84 (2007)
DOI:10.1038/nrc2167
Reference
  Authors
Dilruba S, Kalayda GV
  Title
Platinum-based drugs: past, present and future.
  Journal
Cancer Chemother Pharmacol 77:1103-24 (2016)
DOI:10.1007/s00280-016-2976-z
Reference
  Authors
Lu HP, Chao CC
  Title
Cancer cells acquire resistance to anticancer drugs: an update.
  Journal
Biomed J 35:464-72 (2012)
DOI:10.4103/2319-4170.104411
Reference
  Authors
Koster R, van Vugt MA, Timmer-Bosscha H, Gietema JA, de Jong S
  Title
Unravelling mechanisms of cisplatin sensitivity and resistance in testicular cancer.
  Journal
Expert Rev Mol Med 15:e12 (2013)
DOI:10.1017/erm.2013.13
Reference
  Authors
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G
  Title
Molecular mechanisms of cisplatin resistance.
  Journal
Oncogene 31:1869-83 (2012)
DOI:10.1038/onc.2011.384
Reference
  Authors
Stewart DJ
  Title
Mechanisms of resistance to cisplatin and carboplatin.
  Journal
Crit Rev Oncol Hematol 63:12-31 (2007)
DOI:10.1016/j.critrevonc.2007.02.001
Reference
  Authors
Koberle B, Tomicic MT, Usanova S, Kaina B
  Title
Cisplatin resistance: preclinical findings and clinical implications.
  Journal
Biochim Biophys Acta 1806:172-82 (2010)
DOI:10.1016/j.bbcan.2010.07.004
Reference
  Authors
Jacobsen C, Honecker F
  Title
Cisplatin resistance in germ cell tumours: models and mechanisms.
  Journal
Andrology 3:111-21 (2015)
DOI:10.1111/andr.299
Reference
  Authors
Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK
  Title
Chemoresistance in human ovarian cancer: the role of apoptotic regulators.
  Journal
Reprod Biol Endocrinol 1:66 (2003)
DOI:10.1186/1477-7827-1-66
Reference
  Authors
Sousa GF, Wlodarczyk SR, Monteiro G.
  Title
Carboplatin: molecular mechanisms of action associated with chemoresistance.
  Journal
Brazillian Journal of Pharmaceutical Sciences 50 (2014)
DOI:10.1590/S1984-82502014000400004
Reference
  Authors
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G
  Title
Systems biology of cisplatin resistance: past, present and future.
  Journal
Cell Death Dis 5:e1257 (2014)
DOI:10.1038/cddis.2013.428
Reference
  Authors
Dasari S, Tchounwou PB
  Title
Cisplatin in cancer therapy: molecular mechanisms of action.
  Journal
Eur J Pharmacol 740:364-78 (2014)
DOI:10.1016/j.ejphar.2014.07.025
Reference
  Authors
Basu A, Krishnamurthy S
  Title
Cellular responses to Cisplatin-induced DNA damage.
  Journal
J Nucleic Acids 2010:201367 (2010)
DOI:10.4061/2010/201367
Reference
  Authors
Chaudhry P, Asselin E
  Title
Resistance to chemotherapy and hormone therapy in endometrial cancer.
  Journal
Endocr Relat Cancer 16:363-80 (2009)
DOI:10.1677/ERC-08-0266
Reference
  Authors
Li X, Lin Z, Zhang B, Guo L, Liu S, Li H, Zhang J, Ye Q
  Title
beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1.
  Journal
Sci Rep 6:21010 (2016)
DOI:10.1038/srep21010
Reference
  Authors
Safaei R, Howell SB
  Title
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs.
  Journal
Crit Rev Oncol Hematol 53:13-23 (2005)
DOI:10.1016/j.critrevonc.2004.09.007
KO pathway
ko01524   

DBGET integrated database retrieval system